UCB (NASDAQ:UCBJF) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson’s disease. It also provides therapy in the areas of oncology, immunology, inflammation, allergy and respiratory diseases. UCB delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. “
UCB (UCBJF) traded up 0.60% during trading on Tuesday, hitting $70.59. The stock had a trading volume of 360 shares. The stock has a market cap of $13.28 billion and a PE ratio of 17.00. The firm’s 50-day moving average price is $69.35 and its 200-day moving average price is $72.12. UCB has a 1-year low of $58.42 and a 1-year high of $86.75.
TRADEMARK VIOLATION WARNING: “UCB (UCBJF) Downgraded to Hold at Zacks Investment Research” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2017/10/10/ucb-ucbjf-downgraded-to-hold-at-zacks-investment-research.html.
What are top analysts saying about UCB? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for UCB and related companies.